Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 41Cyclophosphamide 23Peripheral Blood Stem Cell Transplantation 15Lenalidomide 14ibrutinib 11fludarabine phosphate 11Etoposide 10Bortezomib 10Filgrastim 9Bendamustine Hydrochloride 9Mycophenolic Acid 8Melphalan 8Cytarabine 8venetoclax 7fludarabine 7Whole-Body Irradiation 7Vincristine 7Cyclosporine 7CT-P10 7Methotrexate 6obinutuzumab 5acalabrutinib 5Doxorubicin 5Carmustine 5Carboplatin 5Biopsy 5pembrolizumab 4ibritumomab tiuxetan 4carmustine, poliferprosan 20 drug combination 4Tacrolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Mantle-Cell × copanlisib × Clear all
NCT04939272 2026-04-20

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Active not recruiting
8 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT03877055 2022-12-14

A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
8 enrolled 7 charts
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡